For a while now, Bayer and Johnson & Johnson's Xarelto has had no problem besting its competition, zooming to the lead in the new-age anticoagulant market, despite entering second. Now, though, the notion that rival Eliquis is a superior med is permeating the field, and it's up to the companies to quash that idea if they want to keep their hold on the No. 1 spot.
Eliquis, Pfizer and Bristol-Myers Squibb's new-age anticoagulant, got off to somewhat of a rocky start. The third entrant in the warfarin replacement market, the drug lagged well behind competitors last year, with EP Vantage estimating in October that analysts' 2014 sales estimates had fallen 60% within 12 months. Now, however, the drug is finally showing signs of life.
Bristol-Myers Squibb says its Eliquis DTC campaign is doing its part to help get sales where the company wants them. Revenues for the anticoagulant may not be where many analysts expected they'd be when they talked the drug up as a future $3-billion-a-year blockbuster. But they are on the rise--thanks, in part, to the campaign, launched in September. And BMS says it's not stopping there.
China has fast become a huge pillar on the global R&D scene, with local CROs like WuXi PharmaTech and ShangPharma cashing in on demand for clinical trials in the country. But, with the FDA chiding a sloppy Chinese trial run by Bristol-Myers Squibb, Pfizer and PPD, regulators and researchers may think twice before accepting data gathered in the country.
So much for a speedy review of Eliquis, the new anticoagulant from Bristol-Myers Squibb and Pfizer. Best expectation for an approval? Next spring.
Notoriously difficult to dose and manage, warfarin seemed ripe for the overtaking, and the market for new choices was estimated at $10 billion-plus. But as Reuters reports, doctors aren't as enthusiastic as market-watchers have been.
European regulators say the upside of blockbuster drug Pradaxa still outweighs its the risks of fatal bleeding, but they want some more labeling caveats for the blockbuster drug.
The anticoagulant won a thumbs-up from FDA reviewers ahead of Wednesday's advisory panel meeting, where FDA experts will weigh a lucrative new indication.
NICE has recommended the drug for stroke and embolisms in draft guidance, and final guidance may come in April.
Pfizer ($PFE) and Bristol-Myers Squibb ($BMY) will have to wait three more months for the FDA's latest word on Eliquis. The anticoagulant drug has some of the strongest data among a new cadre of...